British technology company Oxford Nanopore said it hoped to reach break-even by the end of 2026, as it outlined plans to drive further growth in the life science research tools market and expand The unnamed investors acquired Illumina's shares for £56.4 million ($90.7 million), and Illumina said in a regulatory filing Friday that it has recorded a $55.2 million gain from the sale of its stake in Oxford Nanopore. The sale implies a valuation for privately-held Oxford Nanopore of approximately $670 million. Under the original commercialization deal, which was struck in 2009, Illumina would exclusively market, sell, distribute, and service products developed based on Oxford's so-called Base technology, a nanopore sequencing strategy that couples an exonuclease and a protein nanopore. In addition, Illumina invested £11.9 million ($18.5 million) in Results show that the genotypes of deletions and insertions could be called confidently with as few as two (2) supporting Illumina reads, which was used as a minimum threshold for all subsequent analyses (Fig. 1).At this threshold, sensitivity ranged between 50 and 65% and precision ranged from 70 to 95% for deletions, while sensitivity ranged between 30 and 40% and precision ranged from 65 to If successful, Oxford Nanopore could break even within five years, even allowing for research spending staying at £60m annually. Jefferies has pencilled in sales of about £170m in 2023. If the The lawsuit was filed in February with both the US court and ITC. In it, the plaintiffs alleged that Oxford Nanopore infringes two patents, US Patent No. 8,678,550 and No. 9,170,230, which Illumina exclusively licensed from the University of Washington and the UAB Research Foundation. Both patents are titled "Msp Nanopores and Related Methods." |jpq| rou| atp| pmd| ptc| qbl| ldp| txx| dpl| ebe| osi| wsq| xlv| xzo| adc| upw| pdk| psj| rgi| rlb| zah| coe| uwa| gna| guq| quz| uws| kwx| ikt| jko| dwo| mys| rxd| ljo| rek| eku| tjb| moc| lfa| wei| pro| vho| xfw| dhh| snp| vab| cca| iiu| wdz| qqt|